Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care ACA Formulary Coverage Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCommunity-CarePolicy N/A

    CommunityCare ACA Formulary / Drug List (partial)

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines which prescription drugs are covered under the CommunityCare ACA formulary and explains member requirements, pharmacy network use, and common utilization controls (prior authorization, quantity limits, step therapy). Applies to members of CommunityCare ACA Individual Silver, Gold, and Expanded Bronze Standardized Plans.

    Policy Summary
    PayerCommunity-Care
    PolicyCommunityCare ACA Formulary / Drug List (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation when the drug line indicates PA or PA**.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    quarterlyformulary publication frequency
    72hstandard exception decision timeframe
    24hexpedited exception timeframe
    multipleentries with quantity limits
    severalproducts requiring PA for high strength

    Coverage Criteria and Formulary Overview

    Standard Coverage Criteria

    Covered when ALL of the following are met

    Basic formulary coverage: Drug is listed on the CommunityCare ACA drug list

    From drug list coverage description

    Medical necessity: Use is medically necessary as determined by the plan

    Coverage contingent on medical necessity

    Network pharmacy: Prescription is filled at a CommunityCare ACA network pharmacy

    Member must use network pharmacies to fill prescriptions

    Utilization Controls

    Additional utilization controls may apply

    Policy Summary
    PayerCommunity-Care
    PolicyCommunityCare ACA Formulary / Drug List (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation when the drug line indicates PA or PA**.
    SourceLink
    On This Page
    Coverage Criteria and Formulary OverviewFormulary Product Listings and Coding NotesAuthorization, Documentation, and Step-Therapy RequirementsInitial Therapy Limits and ConditionsStep Therapy Rules and Affected ProductsSpecified Quantity Limits by ProductKey Definitions and Formulary TermsPolicy Background and Scope
    Utilization controls: Prior Authorization OR Step Therapy OR Quantity Limits may be required depending on the drug

    Requirements/Limits column indicates specific controls (PA, ST, QL)

    Formulary coverage overview

    Coverage is tiered with utilization management applied as indicated per product

    General formulary rules: Each listed product includes a formulary tier and may have ST, QL, and/or PA applied; high-strength opioid formulations commonly require PA and many oral opioids have initial 7-day limits.see product-specific QL/PA flags

    Refer to individual product lines for exact QL values and PA requirement.

    General coverage with utilization controls

    Coverage subject to fulfillment of listed utilization controls

    General formulary controls: Drugs listed are subject to formulary tier assignment and any associated requirements such as PA, ST, and QL as noted for each product.

    See individual product entries for specific limits.

    Age-based PA for nitrofurantoin

    High risk medication age-based PA

    Nitrofurantoin age PA: Nitrofurantoin formulations require prior authorization for members age 70 and older.age >= 70

    High Risk Medications require PA for members age 70 and older.

    Parenteral antibiotic QL rules

    Quantity-limited parenteral agents

    Vancomycin IV limits: Vancomycin IV formulations have quantity limits with daily vial limits and an initial limit allowing up to a 14‑day course per 365 days.e.g., 2 vials per day; initial up to 14 days per 365 days

    Applies to multiple vial sizes as listed in the formulary.

    Formulary coverage controls

    Coverage and utilization controls by drug entry

    Formulary tier assignment: Each listed drug is assigned a formulary tier (Tier 1 through Tier 4) as shown adjacent to the drug name.

    Tier shown on product line item

    Prior authorization requirement: Drugs annotated with 'PA' require prior authorization (examples include INBRIJA and other specialty entries).

    PA flag shown on product line item

    Quantity limits: Drugs annotated with 'QL' have specified quantity limits (examples: INBRIJA 300 caps/30 days; ADHD and hypnotic products with QLs ranging from 15 to 180 units per 30 days).

    See product-level QL values in the formulary

    Step therapy: Drugs annotated with 'ST' require step therapy before coverage (examples: VRAYLAR, QULIPTA, UBRELVY, AIMOVIG, EMGALITY where 'ST' is noted).

    ST indicated in Requirements/Limits column

    Migraine monoclonal antibodies (coverage with PA and QL)

    Coverage and utilization controls apply as stated per drug: agents are covered subject to tier, QL, ST, and PA where indicated.

    PA and QL for specialty migraine biologics: AIMOVIG, EMGALITY and similar monoclonal antibodies are listed with step therapy, quantity limits (typically 1 injection every 30 days) and require prior authorization (PA**); EMGALITY allows an initial loading dose exception (2 injections in 30 days).1 injection every 30 days; loading dose exception where noted

    Follow product-specific ST/PA/QL and loading-dose rules

    Endocrine specialty agents (coverage with PA and QL)

    Endocrine and metabolic specialty injectables require PA and have specified QLs.

    Somatostatin and growth-related agents: Octreotide, lanreotide (SOMATULINE DEPOT), and pegvisomant (SOMAVERT) are Tier 4 and require prior authorization with explicit quantity limits (for example, SOMATULINE DEPOT: QL 1 injection every 28 days).1 injection every 28 days / product-specific vial limits

    PA required for coverage

    Acute migraine agents (coverage with QL; some ST/PA)

    Triptans and acute migraine therapies are generally covered with quantity limits; some combination products require PA and ST.

    Triptan QL examples: Many triptans (almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan) have quantity limits ranging from about 12 to 24 units per 30 days depending on formulation; some combination products (e.g., sumatriptan-naproxen) carry ST and PA requirements.QL ranges by product (e.g., 12 tabs/30 days, 24 sprays/30 days)

    Check the Requirements/Limits column for product-specific ST/PA/QL

    General coverage logic for listed endocrine/metabolic drugs

    Covered when the product is prescribed and any listed utilization management (PA, ST, QL) conditions are satisfied

    Generic structure: Coverage follows formulary tier; if an entry lists PA or ST the prior authorization or step therapy requirements must be met prior to coverage; quantity limits must not be exceeded.

    Product-level specifics are in the drug listings; providers must follow those requirements

    Coverage conditional on administrative requirements

    Coverage for listed agents is subject to PA and adherence to QL/ST where specified; some agents are labeled as preferred for particular indications.

    General coverage conditions: Drug is listed on formulary with Tier and if PA/QL/ST are specified, those requirements must be met for coverage.

    Examples include ACTEMRA (PA, QL), ADALIMUMAB products (PA, QL), and preferred labeling for certain agents (e.g., COSENTYX, PYZCHIVA).

    Drugs that are not listed on the CommunityCare ACA Formulary (Drug List) are generally not covered unless an exception is granted. Members or prescribers may request a formulary exception by contacting CommunityCare Pharmacy Help Desk; the policy directs callers to confirm coverage and, where appropriate, request an exception or identify therapeutically equivalent covered alternatives. Coverage remains subject to plan rules, medical necessity determination, and the requirement that prescriptions be filled at an in‑network pharmacy. (See CommunityCare Pharmacy Help Desk contact and quarterly publication details.)

    Goodsense Aspirin (enteric coated) is listed as an over‑the‑counter product with special coverage: it carries a $0 copay for members at risk for preeclampsia; for members who are not at risk for preeclampsia the entry is listed as OTC; otherwise not covered. Providers should document member risk status when requesting coverage under this exception.

    Within the listed sections there are no explicit clinical exclusions stated (for example, there are no blanket medically inappropriate uses called out in these extracts). Instead, coverage decisions are governed by product‑level utilization controls such as prior authorization, step therapy, and quantity limits as noted in each drug line.

    The document does not present broad blanket exclusions in the cited segments. Rather, individual products may be designated non‑preferred or subject to utilization management (for example, PA or QL) and certain high‑risk medicines require age‑based prior authorization. Any specific non‑coverage statements are made at the product level rather than as sweeping formulary exclusions.

    Formulary Product Listings and Coding Notes

    Authorization, Documentation, and Step-Therapy Requirements

    Prior Authorization

    Prior Authorization Required — Certain drugs require prior authorization before dispensing; high‑strength formulations require PA

    Prior Authorization Required — CommunityCare requires prior authorization (PA) for many drugs and high‑strength formulations. Failure to obtain PA may result in denial of coverage.

    • High‑strength opioid formulations (e.g., select fentanyl, hydrocodone, oxycodone, oxymorphone, morphine beads/tbcr, tramadol high‑strength, XTAMPZA ER 36mg, NUCYNTA ER high strengths) require PA.
    • Many morphine high‑strength products (e.g., morphine sulfate beads 120mg, tbcr high strengths) are PA‑required; select oral/liquid morphine products have quantity limits and initial 7‑day limits.
    • Some hydrocodone and fentanyl high‑strength patches/lozenges denote: “High Strength Requires PA.”
    Prior Authorization

    Prior authorization for high‑strength opioids — Certain high‑strength opioid formulations require prior authorization

    Prior authorization is required for some high‑strength opioid formulations and many opioid products are also subject to step therapy (ST) and quantity limits (QL). Document the indication and strength when submitting PA.

    • Opioid analgesics often have ST and QL (initial 7‑day limits for many immediate‑release opioids).
    • High‑strength entries explicitly state “High Strength Requires PA” — prescribers must document medical necessity and strength.
    • Examples: fentanyl high‑strength patches and lozenges; hydrocodone t24a 100/120mg; oxycodone/oxymorphone high‑strength formulations; morphine beads/tbcr 120mg.
    Prior Authorization

    CABENUVA PA & QL — CABENUVA injection kits require PA and have quantity limits

    CABENUVA injection kits require prior authorization and are subject to quantity limits. Initial loading dose rules apply per formulary.

    • CABENUVA SUS 400‑600: PA; QL (1 kit every 30 days).
    • CABENUVA SUS 600‑900: PA; QL (1 kit every 60 days). Loading dose of 1 kit in 30 days allowed for initial fill.
    • Prescribers must document indication and request PA prior to administration or dispensing.
    Prior Authorization

    Hepatitis C agents PA & QL — EPCLUSA and HARVONI products require PA and have specific QL

    Hepatitis C direct‑acting antivirals commonly require prior authorization and have specific quantity limits; some products also require step therapy.

    • EPCLUSA (tablets/paks): PA; QL (28 tabs/pellets every 28 days).
    • HARVONI (tabs/paks): PA; QL (28 tabs/pellets every 28 days).
    • SOVALDI and related sofosbuvir products: ST; PA; QL (28 or 56 pellets/tabs as listed).
    • VOSEVI: PA; QL (28 tabs every 28 days).
    • PA/QL documentation and indication must be submitted with requests.
    Prior Authorization

    Prior authorization required for many specialty agents — Prior authorization is required for many listed high‑cost or specialty agents

    Prior authorization is required for many specialty, high‑cost, oncology, hematologic, immunologic, and physician‑administered agents. Quantity limits and step therapy requirements frequently apply.

    • Many oral antineoplastics (e.g., venetoclax, dasatinib, erlotinib, imatinib, everolimus, axitinib, ribociclib) require PA and have QLs (tab count or dosing packs).
    • Physician‑administered biologics and immunologic agents (e.g., ACTEMRA, INFLIXIMAB, SIMPONI ARIA, SKYRIZI, STELARA) require PA and have QLs (vials/syringes per dosing interval).
    • Hematologic agents (e.g., VENCLEXTA, KADCYLA, pegfilgrastim products) are PA and QL controlled.
    • Prescribers must document diagnosis, dosing schedule, quantity, and rationale when requesting PA for these agents.
    Prior Authorization

    PA required for select migraine agents — Migraine agents listed with 'PA**' require prior authorization per formulary notes

    Select migraine therapies are subject to step therapy and prior authorization per formulary notes; many monoclonal antibody migraine preventives require PA and QL.

    • Acute and preventive migraine agents such as QULIPTA and UBRELVY show ST and PA** designations.
    • Monoclonal antibodies (AIMOVIG, EMGALITY, etc.) show ST, QL (injections per 30 days) and PA** — loading‑dose exceptions noted (e.g., EMGALITY).
    • Submit prior authorization with prior trial history to satisfy ST where applicable.
    Prior Authorization

    PA for endocrine and metabolic specialty agents — PA required for many endocrine/somatostatin and somatropin‑related products

    Many endocrine, metabolic and specialty hormone agents require prior authorization and have quantity limits; some agents also invoke step therapy.

    • Somatostatin analogs and growth modulators (octreotide, lanreotide, pegvisomant) — PA and QL specified (ml/vials or injections per period).
    • GLP‑1 and incretin agents (liraglutide, MOUNJARO, OZEMPIC, TRULICITY) — PA and QL applied (pens per 28/30 days).
    • Combination and select oral antidiabetics (JANUMET, SYNJARDY, GLYXAMBI) show ST; PA**.
    • Prescribers must document prior treatments when PA or ST is indicated and include quantity and intended dosing frequency.
    Prior Authorization

    PA required for select drugs/devices — Prior authorization (PA) is required for certain medications/devices noted as 'PA'

    Certain drugs and devices across the formulary require PA; this includes some pumps, specialty devices, and vaccine age‑based limitations.

    • Insulin infusion pumps and refill kits (TWIIST, V‑GO) are listed with coverage entries — confirm PA if indicated by plan.
    • VOWST CAPS (fecal microbiota spores) — PA; QL (12 caps every 30 days).
    • Some vaccines and devices may have age‑based coverage limits — check formulary entries and submit PA when required.
    Prior Authorization

    VIBERZI (eluxadoline) PA — VIBERZI requires prior authorization

    VIBERZI (eluxadoline) is subject to prior authorization per formulary requirements.

    • VIBERZI TABS 75mg, 100mg — Requirements/Limits indicate PA.
    Prior Authorization

    Hematologic/selected GI agents PA — Selected agents require prior authorization; see formulary entries

    Hematologic agents and selected GI therapies (including many physician‑administered biologics) require PA and often have QLs documented in the formulary.

    • Hematopoietic growth factors (e.g., ARANESP, pegfilgrastim biosimilars) — PA; QL per dosing interval.
    • Multiple biologic agents for autoimmune and GI indications (e.g., STELARA, SKYRIZI, TREMFYA) — PA and QL (vials/syringes per days/weeks/months).
    • Submit dosing schedule and indication with PA requests for these agents.
    Note

    Prior authorization/tier notes — Listing assigns tiers and 'Requirements/Limits' but specific prior‑authorization criteria not present here

    Formulary entries list tiers and Requirements/Limits (PA, ST, QL). Where PA is indicated, follow the plan's prior authorization process and include complete documentation to avoid delays or denials.

    • Requirements/Limits column indicates applicable PA, ST, and QL details — review for each product prior to prescribing.
    • Some entries use PA** to denote additional PA/step‑therapy requirements — follow the plan’s defined PA criteria.
    • Prior Authorization Risk: Failure to obtain required PA may result in noncoverage.
    Denial Risk

    Prior Authorization Risk — Failure to obtain prior authorization may result in the drug not being covered

    Failure to obtain prior authorization when required may result in the drug not being covered. Providers should obtain PA before dispensing and include supporting documentation to avoid member financial liability.

    • If an exception is requested, submit the prescriber's supporting statement. Expedited exceptions: decision within 24 hours after receiving prescriber support.
    • Decisions for standard exceptions will be made within 72 hours of receipt of necessary information.
    Documentation Required

    Exception Request Documentation — Submit prescriber's supporting statement for exceptions; expedited requests require prescriber support

    When requesting an exception or a PA, submit clinical documentation that justifies medical necessity, specifies the indication, dose/strength, and the requested quantity and duration.

    • Exception Request Documentation: include prescriber's supporting statement; expedited requests require prescriber support for faster review.
    • Document indication, strength, dose, and quantity for PA requests — especially important for high‑strength opioids, CABENUVA, hepatitis C agents, and oncology agents.
    • CABENUVA documentation: include intended kit (loading vs maintenance), dosing interval, and rationale for PA.
    • Hepatitis C DAAs (EPCLUSA, HARVONI, SOVALDI, VOSEVI): include genotype/indication, prior treatment history, and quantity requested (28‑ or 56‑day packs).
    • Documentation to support PA/QL: supply diagnosis, prior therapies tried (for ST), dosing schedule, planned monitoring, and expected duration of therapy.
    • Quantity limit documentation: when requesting override of a QL, provide clinical justification and planned duration.
    • Folic acid and specific PPI formulations, bowel preps, PEG products, and select oral agents may have QLs — document why a different quantity or formulation is needed.
    • VOWST CAPS: PA and QL (12 caps every 30 days) — include indication and prior therapies tried.
    • Provide all supporting clinical records with the PA submission to avoid delays.
    Step Therapy

    Step Therapy Requirement — Step therapy is required for some drugs—members must try preferred first‑line drugs before alternatives are covered

    Step therapy (ST) is common across many therapeutic classes. Where ST is required, prescribers must document trials of preferred agents before a nonpreferred drug will be approved.

    • ST applies to many analgesics and select hepatitis C entries (SOVALDI PACK entries include ST).
    • ST/PA triggers are noted for migraine agents, certain psychiatric and endocrine combination products (e.g., VRAYLAR, JANUMET, SOLIQUA, XULTOPHY, SYNJARDY).
    • For physician‑administered immunologic agents, ST plus PA and QL often apply before coverage is authorized.

    Initial Therapy Limits and Conditions

    Initial therapy limits

    Initial short-course limits: Multiple oral opioid formulations are subject to an initial 7‑day supply limit as noted per product line items.7-day initial limit

    Applies to numerous listed oral opioids (see Analgesics section)

    Initial therapy controls

    Examples where step therapy/PA applies to initial fills

    Initial authorization constraints: Some agents require step therapy and/or prior authorization for initial therapy (examples: VRAYLAR 'ST; PA**', QULIPTA 'ST, QL; PA**', UBRELVY 'ST, QL; PA**').

    Follow ST/PA annotation on drug line for initiation

    Initial dosing exceptions

    Initial therapy controls where specified.

    EMGALITY initial loading dose: EMGALITY permits a loading dose of 2 injections within 30 days for the initial fill; subsequent QL is 1 injection every 30 days and PA applies.2 injections in 30 days for loading

    EMGALITY-specific initial dosing exception

    Initial therapy rules (product-level)

    Initial coverage conditions reflect formulary management entries for each product.

    Product PA/ST/QL: For initiation of listed agents, prescriber must meet any prior authorization or step therapy requirements and adhere to quantity limits as specified in the formulary line item (examples: JANUMET entries show ST; PA**, MOUNJARO requires PA and QL of 4 pens every 28 days).

    See product-specific Requirements/Limits fields

    Bowel prep age-based coverage

    Bowel prep and laxative coverage/tiering notes for age-based $0 copay

    Age-based coverage: Certain bowel‑preparation products are Tier 0 with a $0 copay for members age 45 through 75; outside that age band coverage varies or may be 'not covered'.age 45 through 75

    See Laxatives section for product-level age-based $0 copay rules

    Initial therapy PA/QL

    Initial coverage requirements are mainly administrative controls.

    Initial authorization: Agent is on formulary with a Tier designation; prior authorization and adherence to quantity limits (and step therapy where listed) are required at initiation.see QL per agent

    Examples: ACTEMRA: ST, PA, QL; ADALIMUMAB products: PA, QL; DOPTELET entries show PA and QL

    Step Therapy Rules and Affected Products

    Drug / classStep therapy requirement
    Acetaminophen with codeine (solutions and tablets)ST; subject to initial 7‑day limit and QL as noted (e.g., 2700 mL or 400/360/180 tabs per 30 days)
    Codeine sulfate (30 mg and 60 mg)ST; QL (42 tabs every 30 days); subject to initial 7‑day limit
    Endocet (multiple strengths)ST; QL per strength (examples: 180–360 tabs every 30 days); subject to initial 7‑day limit
    Fentanyl patches and lozengesST for many patch strengths; higher-strength patches marked ST, PA (High Strength Requires PA); QL applies (e.g., 10 patches/30 days; lozenges QL)
    Morphine sulfate (beads, CP24)ST; some high‑strength presentations require PA; QL as listed; initial 7‑day limit applies
    OxymorphoneST; PA for high‑strength forms; QL indicated where listed
    Tramadol (various presentations)ST; QL per formulation (examples: 30–180 tabs/30 days); initial 7‑day limit for many oral opioids
    Tapentadol (NUCYNTA) immediate-release & ERST; QL by strength (e.g., 60–120 tabs/30 days); ER and high strengths may require PA
    Belbuca (buprenorphine film)ST; QL (e.g., 60 films every 30 days) where indicated
    Drug / classStep therapy before
    Many oral opioid analgesics (e.g., oxycodone, endocet, morphine beads)ST applied before alternative or higher‑tier opioid products are covered; initial fill limits also apply (7‑day initial)
    Tapentadol (NUCYNTA) formulationsST required prior to coverage of certain strengths; ER/high‑strength forms may require PA in addition to ST
    Tramadol immediate and extended formulationsST required before coverage of some formulations; QL differs by presentation
    ProductAuthorization requirement
    CABENUVA SUS 400–600 (cabotegravir & rilpivirine)PA required; QL = 1 kit every 30 days; loading dose allowance for initial fill
    CABENUVA SUS 600–900 (cabotegravir & rilpivirine)PA required; QL = 1 kit every 60 days; loading dose allowance for initial fill
    SOVALDI presentationStep therapy / other requirements
    SOVALDI PACK 200 mgST, PA, QL (56 pellets every 28 days) — step therapy indicated in Requirements/Limits
    SOVALDI TABS 200 mg, 400 mgST, PA, QL (28 tabs every 28 days) — step therapy indicated in Requirements/Limits
    Example agentStep therapy / notes
    VRAYLAR (cariprazine)ST; PA** indicated in listing — step therapy required before approval (per formulary line)
    QULIPTA (atogepant)ST; QL (30 tabs/30 days); PA** — step therapy required prior to coverage
    UBRELVY (ubrogepant)ST; QL (16 tabs/30 days); PA** — step therapy required prior to coverage
    AIMOVIG (erenumab)ST; QL (1 injection every 30 days); PA** — step therapy required prior to coverage
    EMGALITY (galcanezumab)ST; QL (1 injection every 30 days or loading dose variants); PA** — step therapy required prior to coverage
    Product examplesStep therapy / formulary annotation
    QULIPTA (atogepant)ST; QL (30 tabs every 30 days); PA** indicated
    UBRELVY (ubrogepant)ST; QL (16 tabs every 30 days); PA** indicated
    DPP‑4 inhibitors and combination antidiabetics (e.g., JANUMET, GLYXAMBI, SYNJARDY, SOLIQUA, XULTOPHY)Many entries list ST; PA** may apply — step therapy required prior to coverage as annotated
    Formulary noteStep therapy implication
    Products annotated with 'ST' in endocrine/metabolic sections (e.g., JANUMET, GLYXAMBI, SYNJARDY, SOLIQUA, XULTOPHY)Step therapy required where 'ST' appears; PA may also apply (PA** annotation) before coverage
    DPP‑4 inhibitors (alogliptin, JANUVIA)Marked ST; PA** — step therapy required prior to coverage per listing
    ProductAuthorization / step notes
    Various presentations of SYNAREL (nafarelin acetate)Listed with 'PA' — prior authorization/authorization step may be required prior to coverage
    Deflazacort preparations (examples)PA and QL noted (e.g., deflazacort susp QL 52 mL/30 days) — authorization needed per listing
    ObservationImplication for step therapy
    No explicit multi‑step sequences provided in the excerptFormulary relies on tier, ST and PA flags per product line; explicit step sequences (e.g., required first‑line agents) are not listed in this excerpt
    Example entriesStep therapy / other requirements
    ACTEMRA (physician‑administered presentations)ST indicated alongside PA and QL (e.g., ST, PA, QL — 20/8/4 vials every 28 days depending on presentation) — step therapy required where shown
    SIMPONI ARIA, SKYRIZI, STELARA and similar biologicsPA and QL commonly listed; some physician‑administered agents also show ST where indicated — step therapy required prior to authorization when 'ST' appears

    Specified Quantity Limits by Product

    diclofenac sodium (topical) gel 1%
    Drugdiclofenac sodium (topical) gel 1% — 300 g
    Source entryVOLTAREN ARTHRITIS PAIN GEL 1% — QL (300g every 30)
    ketorolac tablets
    Drugketorolac tromethamine tablets — QL 20 tabs every 30 days
    Source entryketorolac tromethamine tabs 10mg — QL (20 tabs every 30 days)
    selected opioid products — utilization controls
    Selected opioid products — initial limitSubject to initial 7-day supply restriction for many oral opioids
    Monthly QLs vary by productExamples in listing show QLs per product/strength (see fentanyl, hydrocodone, morphine entries)
    High-strength formulationsCertain high-strength products require PA (listed as 'High Strength Requires PA')
    acetaminophen with codeine solution
    Drugacetaminophen with codeine soln 120-12 mg/5ml — QL 2700 mL every 30 days
    ContextRequirements/Limits notes indicate ST and initial 7-day limit also apply
    fentanyl pt72 patches (selected strengths)
    DrugFentanyl pt72 patches (selected strengths) — QL 10 patches every 30 days
    NoteHigher-strength patch strengths annotated 'High Strength Requires PA' in listing
    fentanyl citrate lozenges
    DrugFentanyl citrate lozenges — QL 120 lozenges every 30 days; PA for specified strengths
    Related entriesOther lozenge/lozenge pack QLs shown in Analgesics listing
    Belbuca films
    DrugBelbuca films (buprenorphine) — QL 60 films every 30 days
    High-strength filmsHigher-strength Belbuca films may be subject to PA as noted in Requirements/Limits
    antifungal / antiretroviral examples
    Antifungal/antiretroviral examplesQuantity limits vary by product; examples in listing include multiple QL values (see fluconazole, darunavir)
    Darunavir exampleDarunavir tabs 600mg — QL 60 tabs every 30 days; 800mg — QL 30 tabs every 30 days
    darunavir tabs 600mg
    DrugDarunavir tabs 600 mg — QL 60 tabs every 30 days
    Darunavir 800 mgQL 30 tabs every 30 days (listed separately)
    CABENUVA SUS 400-600
    CABENUVA SUS 400–600QL 1 kit every 30 days
    CABENUVA SUS 600–900QL 1 kit every 60 days; loading dose allowance for initial fill
    CABENUVA SUS 600-900
    CABENUVA SUS 600–900QL 1 kit every 60 days
    Loading doseLoading dose of 1 kit in 30 days allowed for initial fill
    EPCLUSA TAB 200-50MG
    EPCLUSA TAB 200-50MGQL 28 tabs every 28 days
    EPCLUSA TAB 400-100QL 28 tabs every 28 days (also listed)
    EPCLUSA PAK 150-37.5
    EPCLUSA PAK 150-37.5QL 28 pellets every 28 days
    EPCLUSA PAK 200-50MGQL 56 pellets every 28 days for select pack strengths
    EPCLUSA, HARVONI, SOVALDI, VOSEVI and oncology examples
    Hepatitis C / selected oncology QLsExamples include QL 28 pellets/tabs every 28 days; QL 56 pellets every 28 days; QL 120 tabs every 30 days; vial/day limits as listed
    PA noteMany of these entries require PA in addition to the stated QL
    CAPRELSA 100mg (vandetanib)
    CAPRELSA 100 mg (vandetanib)QL 60 tabs every 30 days
    CAPRELSA 300 mg (vandetanib)QL 30 tabs every 30 days
    CAPRELSA 300mg (vandetanib)
    CAPRELSA 300 mg (vandetanib)QL 30 tabs every 30 days
    CAPRELSA 100 mgQL 60 tabs every 30 days (other strength)
    INLYTA 1mg (axitinib)
    INLYTA 1 mg (axitinib)QL 240 tabs every 30 days
    INLYTA 5 mgQL 120 tabs every 30 days
    KISQALI 200mg 21‑tab pack
    KISQALI 200 mg 21‑tab packQL 21 tabs every 28 days
    Dose pack note21‑tab pack corresponds to the 200 mg dosing regimen listed
    RYDAPT 25mg (midostaurin)
    RYDAPT 25 mg (midostaurin)QL 224 caps every 28 days
    ContextListed under antineoplastic agents with PA and QL
    ZELBORAF 240mg (vemurafenib)
    ZELBORAF 240 mg (vemurafenib)QL 240 tabs every 30 days
    ContextPA and QL listed for this antineoplastic agent
    VISTOGARD pack 10gm (uridine triacetate)
    VISTOGARD pack 10 gm (uridine triacetate)QL 20 packets every 5 days
    IndicationEmergency treatment listing with short interval QL
    INBRIJA
    INBRIJA (levodopa) capsules 42 mgQL 300 caps every 30 days
    Formulary noteListed with PA and QL in Parkinson's/related section
    Multiple ADHD products — example QLs
    ADHD product examplesQuantity limits vary by product — examples include 30, 60, 90, 120, 180 units per 30 days
    SourceADHD sections list multiple QL values by formulation and strength
    Hypnotics — quantity-limit examples
    Hypnotics (eszopiclone, ramelteon, temazepam, zolpidem etc.)Common QL: 15 tabs/caps every 30 days (some agents), or 10 tabs for specific agents
    ExampleEszopiclone, temazepam, zaleplon, zolpidem entries show QL 15 every 30 days
    Migraine injectables — QL examples
    Migraine injectables (AIMOVIG, EMGALITY)AIMOVIG: QL 1 injection every 30 days; EMGALITY: QL 1–3 injections every 30 days depending on presentation; loading dose allowances noted for EMGALITY
    ST/PAThese agents are listed with ST and PA** annotations where applicable
    almotriptan
    almotriptanQL 12 tabs every 30 days
    SourceTriptan listing (almotriptan) shows QL 12 every 30 days
    sumatriptan (spray 5mg/act)
    sumatriptan nasal spray (5 mg/act)QL 24 sprays every 30 days
    SourceTriptan listing shows QL 24 sprays every 30 days for sumatriptan spray
    octreotide acetate soln 200mcg/ml
    Octreotide acetate solution 200 mcg/mlQL 225 mL every 30 days
    ListingEntry shows PA and QL (225 mL every 30 days) for octreotide solution
    SOMATULINE DEPOT (lanreotide)
    SOMATULINE DEPOT (lanreotide)QL 1 injection every 28 days
    AuthorizationListed with PA and QL in endocrine/somatostatin section
    buprenorphine-naloxone SL film/tab
    Buprenorphine‑naloxone SL film/tabQL up to 3 units or tabs daily depending on strength
    Formulary noteVarious SL film/tablet strengths listed with day‑limit QLs and some $0 copay tiers
    Selected GLP‑1 / incretin QLs (examples)
    MOUNJARO (tirzepatide)QL 4 pens every 28 days
    OZEMPIC (semaglutide)QL 3 mL every 28 days
    TRULICITY (dulaglutide)QL 4 pens every 28 days
    KYLEENA IUD 19.5mg
    KYLEENA IUD 19.5 mgQL 1 unit every 300 days
    Formulary contextIUDs listed with QL 1 every 300 days (yearly placement) in contraceptive section
    LILETTA IUD 20.1mcg/day
    LILETTA IUD 20.1 mcg/dayQL 1 unit every 300 days
    ContextListed under contraceptives with QL = 1 every 300 days
    MIRENA IUD 20mcg/day
    MIRENA IUD 20 mcg/dayQL 1 unit every 300 days
    ContextContraceptive listing shows QL 1 every 300 days
    MIUDELLA IUD COPPER
    MIUDELLA IUD (copper)QL 1 unit every 300 days
    Formulary noteCopper IUD listed with same QL frequency as hormonal IUDs
    Blood glucose test strips
    Blood glucose test strips (Accu-Chek, OneTouch)QL 150 test strips every 30 days
    Dexcom sensors (G6/G7)QL 3 sensors every 30 days
    DEXCOM G6 MIS SENSOR
    DEXCOM G6 MIS SENSORQL 3 sensors every 30 days
    ListingContinuous glucose sensor entries specify QL 3 every 30 days
    NEXPLANON implant / other implants / IUDs
    NEXPLANON implant / other implants/IUDsQL 1 unit every 300 days
    ContextImplants and long‑acting contraceptives listed with single‑unit QLs per 300 days
    deflazacort (various forms)
    Deflazacort suspension 22.75 mg/mLQL 52 mL every 30 days
    Deflazacort tablets 6 mgQL 60 tabs every 30 days
    Deflazacort tablets 18/30/36 mgQL 30 tabs every 30 days
    esomeprazole magnesium and other PPIs — annual QL
    Proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)QL 90 caps every 365 days (annual QL)
    Formulary noteAnnual QL applies across listed PPI formulations
    VOWST CAP (fecal microbiota spores, live‑brpk)
    VOWST CAP (fecal microbiota spores, live‑brpk)QL 12 caps every 30 days; PA required
    SUCRAID exampleSUCRAID listed with PA and QL 354 mL every 30 days
    FYLNETRA (pegfilgrastim-pbbk)
    FYLNETRA (pegfilgrastim‑pbbk)QL 2 syringes every 28 days
    Formulary noteHematopoietic growth factors list PA and QL per product
    ALVAIZ tabs (eltrombopag choline) 9mg/54mg
    ALVAIZ tabs (eltrombopag choline) 9 mg/54 mgQL 60 tabs every 30 days
    ALVAIZ tabs 18 mg/36 mgQL 90 tabs every 30 days
    ALVAIZ tabs (eltrombopag choline) 18mg/36mg
    ALVAIZ tabs (eltrombopag choline) 18 mg/36 mgQL 90 tabs every 30 days
    Lower strength9 mg/54 mg presentation QL 60 tabs every 30 days
    DOPTELET (avatrombopag) formulations
    DOPTELET (avatrombopag) formulationsQL varies by pack: 1 carton every 5 days for smaller packs; 2 cartons every 30 days for larger pack
    PADOPTELET entries list PA and QL in thrombocytopenia section
    ADALIMUMAB and various biologics
    ADALIMUMAB and various biologicsQL 4 auto‑injectors or 4 syringes every 28 days (varies by presentation)
    PA noteMost biologic self‑administered agents require PA in addition to QL
    INFLIXIMAB
    INFLIXIMABQL 5 vials every 42 days; PA required
    ContextPhysician‑administered immunologic agents list vial limits and PA
    ALVAIZ (eltrombopag choline)
    ALVAIZ (eltrombopag choline)QL 60 tabs every 30 days (9 mg/54 mg); QL 90 tabs every 30 days (18 mg/36 mg)
    Formulary notePA and QL shown in thrombocytopenia agents section
    DOPTELET (avatrombopag)
    DOPTELET (avatrombopag)QL 1 carton every 5 days; 2 cartons every 30 days for larger pack
    ListingPA and QL indicated in thrombocytopenia section
    folic acid (caps 800mcg; tabs 400/800mcg)
    Folic acid (caps 800 mcg; tabs 400/800 mcg)QL 100 caps/tabs every 30 days; $0 copay for members 55 and younger capable of pregnancy
    Coverage noteOTC designation and $0 copay for eligible members noted in listing

    Key Definitions and Formulary Terms

    Formulary (Drug List) — definition
    Formulary (Drug List)A list of covered drugs selected by CommunityCare ACA; coverage is subject to medical necessity and plan rules; prescriptions must be filled at a network pharmacy
    ImplicationRequirements/Limits column indicates PA, QL, ST where applicable
    Tier — definition
    TierCopayment categorization (Tier 0/1/2/3/4) used to determine member cost‑sharing; specialty medications are in a specialty tier
    UseRefer to Schedule of Benefits for exact copayment amounts
    QL — definition
    QL (Quantity Limit)Maximum allowed supply in the defined period as specified in the Requirements/Limits column (e.g., 120 lozenges every 30 days; 28 tabs every 28 days)
    PurposeUsed to limit quantity dispensed per time period for safety and cost management
    ST — definition
    ST (Step Therapy)Requirement to try specified preferred or lower‑tier agents before the requested drug is covered; indicated by 'ST' in Requirements/Limits
    EffectMember must try and fail preferred agent(s) prior to coverage of alternative
    PA — definition
    PA (Prior Authorization)Documented approval required from CommunityCare ACA before coverage is provided; commonly applied to high‑strength or specialty products
    RiskFailure to obtain PA may result in the drug not being covered
    PA** — notation
    PA** annotationIndicates that prior authorization applies if step therapy is as noted (PA applies conditionally with ST)
    UsageUsed in formulary annotations alongside 'ST' to indicate conditional PA
    OTC — definition
    OTCOver‑the‑counter designation for certain products (e.g., aspirin EC entries) — OTC items may have special copay rules
    ImplicationSome OTC items are $0 copay for specific member groups; otherwise not covered
    Preferred agent — definition
    Preferred agentDesignation for agents preferred by the payer for particular indications (e.g., COSENTYX, PYZCHIVA) — indicates payer preference within a therapeutic class
    EffectMay influence step therapy and prior authorization decisions

    Policy Background and Scope

    This formulary groups drugs by therapeutic condition and applies utilization controls to promote safe, effective, and cost‑effective use. Typical controls applied across groups include Prior Authorization (PA), Step Therapy (ST), and Quantity Limits (QL); specialty and high‑risk medications commonly have additional PA/QL/ST requirements. The formulary is maintained and published on a recurring basis and prescriptions must be filled at network pharmacies consistent with plan rules.